Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma

“…We report a patient with BL who, post-CD19 CAR-T cell therapy, experienced both CRS and IEC-HS, resulting in pancytopenia and BM findings most consistent with aplasia requiring emergent transplant for hematopoietic recovery. Hematologic toxicities, especially aplasia, defined as the reduction or absence of hematopoietic progenitor cells, can be detrimental and are seldom described in the literature [ 10 ]. Although prolonged cytopenias can occur after a patient’s post-CAR-T cell therapy, persistent pancytopenia unresponsive to growth factors is a concerning finding [ 17 ].…”

“…Some studies have demonstrated complete response following CAR-T in BL, whereas others have shown rapid progression of disease with high mortality. In the cases exhibited in Table 1 [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ], 76% of patients with R/R BL experienced CR following CAR-T. Although CR was achieved in the majority of these patients, the duration of response was widely variable—some experienced relapse and rapid progression while others achieved durable remission of many months.…”

“…Limited case reports and case series have described mixed outcomes in BL. Durable complete remission following CAR-T has been shown in some cases of BL, whereas the rapid progression of disease or complications of the treatment have led to death in other patients (see Table 1 ) [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ].…”

“…Sci. 2023, 11, 67 2 of 9 CAR-T has been shown in some cases of BL, whereas the rapid progression of disease or complications of the treatment have led to death in other patients (see Table 1) [6][7][8][9][10][11][12][13][14].…”

Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia

“… 36 T cells expressing Hu19-CD828Z have been shown to be effective against lymphoma and to have a low incidence of neurological toxicity in a previous clinical trial conducted by our group. 17 , 37 For this study, we examined different methods to purify T cells from CLL cells, different reagents to activate the T cells, and different cytokines added to the CAR T cell culture media. We developed an optimized protocol for producing autologous anti-CD19 CAR T cells for treating CLL patients.…”